針對新興感染疾病威脅的醫護站診斷(市場分析與技術考察) 是由出版商Kalorama Information在2011年10月所出版的。
這份英文市場調查報告書包含150 Pages 價格從美金3500起跳。
本報告提供醫護站診斷整體市場概要，以及感染疾病的POC市場主要企業簡介， 國際計劃概要，各不同疾病趨勢與到2015年為止的預測等彙整資料，為您概述為以下內容。
第1卷 摘要整理
第2章 感染疾病相關分佈式檢測設備的商業化
- 概要
- 用戶培訓與支援服務
- 連接性支援分散檢測
- 病患的負擔
- 藥物體制複雜化測試環境
- 未滿足需求
- 財政，國際計劃的經濟學
- 結論
第3章 技術考察
- 概要
- 試劑問題
- 設備·非設備
- 血糖試紙的診斷
- 分子診斷的潛力
- 無線通訊
- 小型化
第4章 南美錐蟲病
- 簡介
- 各地區市場
- 國際計劃
- 檢驗現況
- 參與企業
- 檢驗技術:現在和未來
第5章 基孔肯雅熱
- 簡介
- 各地區市場
- 國際計劃
- 檢驗現況
- 參與企業
- 檢驗技術:現在和未來
第6章 登革熱
- 簡介
- 各地區市場
- 國際計劃
- 檢驗現況
- 參與企業
- 檢驗技術:現在和未來
第7章 HIV
- 簡介
- 各地區市場
- 國際計劃
- 檢驗現況
- 參與企業
- 檢驗技術:現在和未來
第8章 人類乳突病毒(HPV)
- 簡介
- 各地區市場
- 國際計劃
- 檢驗現況
- 參與企業
- 檢驗技術:現在和未來
第9章 利什曼症
- 簡介
- 各地區市場
- 國際計劃
- 檢驗現況
- 參與企業
- 檢驗技術:現在和未來
第10章 鉤端螺旋體病
- 簡介
- 各地區市場
- 國際計劃
- 檢驗現況
- 參與企業
- 檢驗技術:現在和未來
第11章 瘧疾
- 簡介
- 各地區市場
- 國際計劃
- 檢驗現況
- 參與企業
- 檢驗技術:現在和未來
第12章 盤尾絲蟲病
- 簡介
- 各地區市場
- 國際計劃
- 檢驗現況
- 參與企業
- 檢驗技術:現在和未來
第13章 STD
- 簡介
- 各地區市場
- 國際計劃
- 檢驗現況
- 參與企業
- 檢驗技術:現在和未來
第14章 結核
- 簡介
- 各地區市場
- 國際計劃
- 檢驗現況
- 參與企業
- 檢驗技術:現在和未來
Abstract
The World Health Organization has identified a group of diseases that are the
world' s most pressing health problems. This represents an opportunity for test
manufacturers, particularly in POC testing. Because of their ability to
deliver fast results at the point of care, rapid testing is a focus area of
healthcare providers and payors in infectious disease prevention. Kalorama
Information has been reporting on the rapid test area for several years and
has identified the segments with the fastest growth, and infectious disease
has surfaced as one of those segments.
This report, Point of Care Diagnostics for Emerging Infectious Disease Threats
(Market Analysis and Technical Considerations), examines this POC segment with
a focus on new threats for which there are markets in the developing world and
in developed countries.
A Unique Approach: Market and Technical Analysis
Tests can only be marketed if they can be manufactured and if they can
function in the healthcare environment. Thus, this report also discusses the
technical choices, possibilities and limitations to today' s POC tests
especially when they are used in the developing world. Reagent issues, testing
on strips, instrumented and non-instrumented tests are coved in this report.
These factors will impact what tests will reach the market and how they will
function.
An Opportunity For Test Makers
Infectious disease is a broad category, and in some disease areas, diagnostic
companies already own market share. Increasingly hospitals and clinics are
seeing new infectious disease threats and tests are being developed to assist
them. Within the infectious disease testing market, this report details the
opportunities that could be found when diseases of the developing world enter
the healthcare system of the developed. This report provides market
projections for point of care diagnostics in the developed and developing
world for the following infectious diseases:
- Chagas Disease, Rapid Test Market Forecast to 2015
- Chikungunya, Rapid Test Market Forecast to 2015
- Dengue Fever, Rapid Test Market Forecast to 2015
- HIV, Rapid Test Market Current Size and Forecast to 2015
- HPV, Rapid Test Market Current Size and Forecast to 2015
- Leishmaniasis, Rapid Test Market Forecast to 2015
- Onchocerciasis (River Blindness), Rapid Test Market Forecast to 2015
- STDs, Rapid Test Market Current Size and Forecast to 2015
- Tuberculosis, Rapid Test Market Forecast to 2015
In addition the report also provides:
- The Overall Point of Care Diagnostics Market Statistics
- Economics of Financial and International Programs
- Company Profiles of Leaders in the POC Infectious Disease Market
- Key Players in the Infectious Disease Rapid Test Market
- Developed and Developing World Opportunities
- Test Volumes in Developing Countries
- Review of Test Products Currently on the Market
- Climate, Water Use and Sample Prep Considerations
- EMR and Connectivity Issues
- Tests in Development
- The Role of Drug Resistance
- Disease Statistics
- POC and Infrastructure Needs
- Comparison of Test Modalities and Sample Collection Methods
Two Industry Experts Provide Unique Insights
Shara Rosen is Kalorama Information' s lead diagnostic industry analyst. She is
the author of seven best-selling editions of The Worldwide Market for In Vitro
Diagnostics, as well as scores of other titles on segments of the IVD Industry.
Brendan O' Farrell is the President of Diagnostic Consulting Network
, a provider of OEM services to developers and manufacturers of
rapid assays. Key services include contract rapid assay system development,
custom reagent development, industry education and training and consulting
services. Among the topics these experts discuss is the number of competitors
who have been successful with efforts in developing countries.
The following companies are discussed in this report:
- 3QBD
- Abbott Diagnostics Access Bio, Inc.
- Acon Laboratories, Inc./Innovacon
- Akers Biosciences, Inc.
- Akonni Biosystems Inc.
- Alere
- American Bionostica, Inc.
- AT First Diagnostic LLC
- Beckman Coulter Inc. Becton Dickinson
- Bhat Bio-tech India (p) Ltd.
- Biocan Diagnostics Inc.
- bioLytical Laboratories
- Biomagnetics Diagnostics Corp.
- Bio-Manguinhos/FioCruz
- bioMerieux
- BioVei Incorporated
- Burnet Institute
- California Institute of Technology (Caltech)
- CapitalBio Corporation
- Catalysis Foundation for Health
- Cellestis Ltd
- Cepheid
- Chembio Diagnostic Systems, Inc.
- Clearbridge BioLoc
- Clinoteck Diagnostics
- Core Diagnostics
- CTK Biotech Inc.
- Diagnostics for All (DFA)
- Diagnostics for the Real World (DRW)
- DIALAB
- DNA Medicine Institute (DMI)
- Eiken Chemical Co., Ltd.
- Enigma Diagnostics Limited
- Epistem Plc
- FK Biotecnologia
- Guardian Technologies International
- Hain Lifescience GmbH
- Hema Diagnostic Systems (HDS)
- i+MED Laboratories Company Limited
- InBios International, Inc.
- Ionian Technologies, Inc.
- IQuum Inc.
- Jal Innovation (S) Pte
- LabNow
- Lifeassay Diagnostics (Pty) Ltd
- Linnodee Ltd.
- LumiQuick Diagnostics, Inc.
- J. Mitra & Co. Pvt Ltd
- MP Biomedicals
- MedMira Inc.
- Micronics, Inc.
- Microskia
- Millennium Biotechnology, Inc. (MBI)
- Omega Diagnostics Group PLC
- Partec GmbH
- PointCare Technologies, Inc.
- QBC Diagnostics, Inc.
- QuantuMDx Group
- Premier Medical Corporation Limited
- Princeton BioMeditech Corporation
- Seventh Sense Biosystems, Inc.
- Signature Mapping Medical Sciences, Inc.
- Span Diagnostics Ltd.
- Standard Diagnostics, Inc.
- Tulip Group
- VEDA.LAB
- Veredus Laboratories Pte
- WAMA Diagnostica
- Zyomyx Inc.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Scope and Methodology
- Emerging Market Trends, diseases and technologies
- World Demand for Decentralized Testing for Infectious Diseases
CHAPTER TWO: COMMERCIALIZATION OF DECENTRALIZED TEST DEVICES FOR INFECTIOUS DISEASES
- Overview
- User Training and Support Services
- Connectivity Supports Decentralized Testing
- The Disease Burden
- Drug Resistance Complicates the Test Landscape
- An Unmet Need
- Economics of Financial and International Programs
- Conclusion
CHAPTER THREE: TECHNICAL CONSIDERATIONS
- Overview
- Reagent Issues
- Instrumented or non-instrumented
- Diagnostics on Paper Test Strips
- The Promise of Decentralized Molecular Diagnostics
- Wireless Communication
- Miniaturization
CHAPTER FOUR: CHAGAS DISEASE
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER FIVE: CHIKUNGUNYA
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER SIX: DENGUE
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER SEVEN: HIV
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER EIGHT: HPV
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER NINE: LEISHMANIASIS
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER TEN: LEPTOSPIROSIS
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER ELEVEN: MALARIA
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER TWELVE: ONCHOCERCIASIS (RIVER BLINDNESS)
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER THIRTEEN: STDs
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER FOURTEEN: TUBERCULOSIS
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
體外診斷(IVD)在發展中國家顯示高成長率
2011年10月27日
Global Information, Inc.已開始銷售Kalorama Information所發行的報告書「Point of Care Diagnostics for Emerging Infectious Disease Threats (Market Analysis and Technical Considerations) (針對新興感染疾病威脅的醫護站診斷(市場分析與技術考察))」
Kalorama Information分析，容易使用、高溫和水少的狀況亦能迅速出現結果的體外診斷(IVD)用檢查，在IVD上有大幅成長、成為下個市場的機會。報告書預測，檢查出瘧疾和結核等感染症、鉤端螺旋體病和屈公病等奇病的檢驗，今後5年將成長為2億5,000萬美元的市場規模。報告書由Kalorama Information的分析者Shara Rosen和Diagnostic Consulting Network的社長Brendan O’Farrell共同執筆。
全球7大致死疾病中，結核、瘧疾、肝炎、尤其是HIV/AIDS依然劇增，到2020年為止HIV/AIDS及結核將佔發展中國家因感染症死亡的絕大多數。由於國際社會對此問題的的反應，形成了市場。針對需要最緊急性處理的疾病，POC試驗的銷售額以13％的成長率增加，比其他POC診斷市場更劇增。
Shara Rosen述說：「轉向迄今被忽視的疾病，因應投入的資金亦擴大。」。「過去10－15年間，政治家和援助團體，不僅是針對感染症的折磨和死亡的原因，亦開始注意到其是阻止經濟發展的重大要因。」
|
